Abstract
Infiltrating inflammatory cells into the kidney mediate the initiation and progression of damage by direct cytotoxicity, the secretion of soluble factors such as cytokines and proteases, or by the subsequent induction of further immune response. Before leukocytes can exert their effects on renal damage or repair, they have to reach the site of injury. It has become clear in recent years that a group of small proteins called chemokines are the chemotactic cytokines considered to be the main regulators of directional leukocyte trafficking under homeostatic and inflammatory conditions. In this review, we summarize available in vivo studies on the neutralization of chemokines and chemokine receptors in renal inflammatory disease, and especially focus on the potential therapeutic effects of chemokine blockade in glomerulonephritis and renal transplantation. Although interference with chemokine expression holds great promises for the treatment of inflammatory renal diseases, it has been shown that such an approach may actually worsen in diseases under certain circumstances. This suggests that inhibition of chemokine expression and action must be time and compartment specific to provide therapeutic benefit for renal structure and function.
Keywords: Chemokine receptor, glomerulonephritis, renal transplantation, inflammation
Current Drug Targets
Title: Kidney Diseases and Chemokines
Volume: 7 Issue: 1
Author(s): Ulf Panzer, Oliver M. Steinmetz, Rolf A.K. Stahl and Gunter Wolf
Affiliation:
Keywords: Chemokine receptor, glomerulonephritis, renal transplantation, inflammation
Abstract: Infiltrating inflammatory cells into the kidney mediate the initiation and progression of damage by direct cytotoxicity, the secretion of soluble factors such as cytokines and proteases, or by the subsequent induction of further immune response. Before leukocytes can exert their effects on renal damage or repair, they have to reach the site of injury. It has become clear in recent years that a group of small proteins called chemokines are the chemotactic cytokines considered to be the main regulators of directional leukocyte trafficking under homeostatic and inflammatory conditions. In this review, we summarize available in vivo studies on the neutralization of chemokines and chemokine receptors in renal inflammatory disease, and especially focus on the potential therapeutic effects of chemokine blockade in glomerulonephritis and renal transplantation. Although interference with chemokine expression holds great promises for the treatment of inflammatory renal diseases, it has been shown that such an approach may actually worsen in diseases under certain circumstances. This suggests that inhibition of chemokine expression and action must be time and compartment specific to provide therapeutic benefit for renal structure and function.
Export Options
About this article
Cite this article as:
Panzer Ulf, Steinmetz M. Oliver, Stahl A.K. Rolf and Wolf Gunter, Kidney Diseases and Chemokines, Current Drug Targets 2006; 7 (1) . https://dx.doi.org/10.2174/138945006775270213
DOI https://dx.doi.org/10.2174/138945006775270213 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology The Role of Nuclear Receptor PPARα in the Sleep-wake Cycle Modulation. A Tentative Approach for Treatment of Sleep Disorders
Current Drug Delivery The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared
Drug Metabolism Letters Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Phenylbutyric Acid Protects Against Spatial Memory Deficits in a Model of Repeated Electroconvulsive Therapy
Current Neurovascular Research Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Preterm Birth, Inflammation and Infection: New Alternative Strategies for their Prevention
Current Pharmaceutical Biotechnology Acute Severe Colitis: Infliximab and/or Cyclosporine?
Current Drug Targets Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets